Back to Search
Start Over
Supplementary Figure 2 from Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
- Publication Year :
- 2023
- Publisher :
- American Association for Cancer Research (AACR), 2023.
-
Abstract
- Supplemental Figure S2. Adverse events in crossover group
Details
- Database :
- OpenAIRE
- Accession number :
- edsair.doi.dedup.....28793f51c06cf4dd88863fe91eeb4c0b